menu
Frédéric Desdouits
Chief Executive Officer - Member of the Governing Board
Before joining Orano Med, he served as CEO of TreeFrog Therapeutics from 2020 to December 2025, a biotech company developing cellular therapies based on a breakthrough cell culture technology.
From 2017 to 2020, he headed pharmaceutical activities at Seqens, a global leader in the manufacturing of specialty ingredients, while also serving as CEO of its publicly listed subsidiary, PCAS. Between 2011 and 2017, he worked at the Pierre Fabre Group, where he established business development activities and oversaw pharmaceutical operations in North America. Earlier in his career, he co-founded and served as managing partner at Bionest Partners (2004–2011), a strategic and financial consulting firm specializing in healthcare and biotechnology, and managed the European Pharma and Biotech team at Exane BNP Paribas (1997–2004).
Since 2022, he has been a member of the Orano Med Governing Board and serves as Vice President of the industry association France Biotech.
Frédéric Desdouits graduated from the École Polytechnique, obtained a PhD in Neurosciences from the University of Paris VI, before going on to do postdoctoral research at the Rockefeller University in New York. He is a CEFA (Certified European Financial Analyst) and Certified in Global Management from INSEAD.